Europe’s life sciences position cannot be taken for granted.
A new EFPIA report, “Assessing Europe’s Competitiveness as a Location for the Life Sciences Industry,” says europe still has a strong scientific base, but is losing ground to the us and china on several key competitiveness measures.
Key findings highlighted in the article:
-
Clinical trials: the eu’s share of global industry-funded trials fell by 50% from 2013–2023; china’s share rose from 8% to 29%.
-
R&D growth: annual r&d investment growth is 5.4% in the eu vs 6.4% in the us and 12.1% in china.
-
Regulatory timelines: average approval time is 430 days in the eu vs 356 days in the us; the eu uses fast-track procedures less than competitors.
-
Launch availability: 39% of global launches are available in europe vs 85% in the us.
The report argues that closing the investment gap could add €105bn in r&d investment over 10 years and calls for action on ip protection, regulatory modernisation, and faster patient access.
Read more at https://www.lif.dk/ny-rapport-europa-har-et-innovationsproblem-og-taber-terraen-i-det-globale-life-science-kaploeb/
